People Vaccinated in the UK (1st dose): 45,978,017

People Vaccinated in the UK (2nd dose): 34,997,491

This glossary will help you understand the most common scientific terms and materials that describe the biology of Coronavirus and the spread of COVID-19.

It can assist in the reading of research papers and help you understand language used in drug and vaccine development. It also has a comprehensive list of international and UK organisations involved in public health, their institutional acronyms and descriptions of their work.

Understanding the biology of the virus

Antigens

Proteins found on the surface of pathogens such as viruses and bacteria. Antigens are unique to each pathogen. The body recognises an antigen on the SARS-CoV-2 virus as foreign and this stimulates an immune response.

Antigenic drift

Occurs when small changes in the pathogen’s genetic material accumulate, so that its antigens become slightly different from their original version. It is a common phenomenon in RNA (defined below) viruses such as SARS-CoV-2.

Carriage

When a virus is present in the body without causing any harm to the person infected, who is asymptomatic or pre-symptomatic.
Coronaviruses – a family of viruses that cause respiratory and gastrointestinal illnesses in people.

COVID-19

Coronavirus disease first recognised in 2019. The disease caused by SARS-CoV-2.

DNA

Deoxyribonucleic acid, a molecule that carries genetic information.

mRNA

Messenger RNA, the ‘ready-to-read’ instructions to produce proteins.

Mutation

A term used to describe how an organism’s genetic material can change. Viral mutations are very common.

Pathogens

Infectious organisms (such as viruses, bacteria or parasites) that can produce a disease. SARS-CoV-2 is a pathogen.

Replication

When a virus makes several copies of itself.

Reservoir

Organism or environment where a virus typically lives and reproduces.

RNA

Ribonucleic acid. A molecule with some similarities to DNA. Its main role is in decoding genetic material to make proteins. In some viruses, RNA carries the genetic code instead of DNA. SARS-CoV-2 is an RNA virus. There are different types of RNA, including messenger RNA (mRNA) and self-amplifying RNA.

SARS-CoV-2

Severe acute respiratory syndrome coronavirus 2, the virus that causes COVID-19.

Spike protein

These are club-shaped structural features that are found on the surface of the SARS-CoV-2 virus. It is the part of the virus that attaches to human cells so the virus can enter and infect them. This protein is a therapeutic target for antivirals; drugs that can interfere in the interaction between the spike protein and the human cells could stop the virus from entering cells and replicating. The spike protein is also central to some COVID-19 vaccines in development. It is an antigen recognised by the body and stimulates an immune response, including the production of antibodies that can neutralise the virus.

Variant

As a virus replicates, it can accumulate mutations. A version of the virus with these mutations is called a ‘variant’. Emergence of variants is a natural phenomenon. Most mutations have very little impact on the virus’s properties, others facilitate transmission or infection of other species. See also antigenic drift.

Virology

The scientific and medical discipline concerned with understanding the biology of viruses and viral diseases, their treatment and prevention. Virologists study common infections such as influenza and chickenpox to new and emerging viruses that cause Ebola, Zika and COVID-19.

Zoonotic disease

Diseases caused by pathogens that originally spread from animals to humans. COVID-19 is a zoonotic disease.

Understanding how COVID-19 spreads and how it can be contained

Accuracy of test

This is often used to describe both accuracy and reliability of a test. For COVID-19 this would mean how good a test is at confirming the presence or absence of an active or previous COVID-19 infection. No diagnostic test or antibody test is 100% accurate.

Antibody test

Detects antibodies to SARS-CoV-2 virus from a current or previous infection.

Antigen test

Detects viral material indicating a current infection. Tests for COVID-19 detect whether viral antigens found on the surface of SARS-CoV-2 are present in a sample.

Asymptomatic

Having an infection but not showing any symptoms.

Case fatality ratio

The proportion of people with symptoms that die.

Contact tracing

Identifying the source and contacts linked to a confirmed case of an infectious disease. Contacts can be classified as high risk, low risk or no risk and given advice on what to do. This approach is used as a public health measure to contain the spread of an infection. Forwards contact tracing refers to finding the people that the person who tested positive could have passed the virus to. Backwards contact tracing refers to finding the individual who gave the virus to the person who subsequently tested positive.

Diagnostic test

A test that can confirm if someone has an active SARS-CoV-2 infection.

Doubling time

The time it takes for the number of infections to double.

Epidemiology

The study of what is causing a certain health outcome (diseases, environmental exposures, injuries), the distribution of diseases in different groups in the population, what causes them and changes over time. Knowledge from epidemiological research is used to design measures to control infectious disease.

Excess mortality

Sometimes called excess deaths, this is the number of additional deaths in a time period that is a higher than would usually be expected. For example, if there were normally 500 deaths in 1 week, but 750 were reported, this would equal 250 excess deaths. At the time of writing there have been 63,401 excess deaths in England since 20 March 2020.

False negative

An incorrect result. For example, when someone with a SARS-CoV-2 infection tests negative.

False positive

An incorrect result. For example, when someone who does not have a SARS-CoV-2 infection tests positive.

Infection fatality ratio

The proportion of infected people that die.

Immunity passport

Documentation that indicates an individual’s immune status. For COVID-19 this could be based on whether someone has been immunised or has antibodies because of a previous infection. There is insufficient evidence about the effectiveness of immunity passports. This is because having SARS-CoV-2 antibodies does not necessarily mean that someone is protected against a second infection. The duration of immunity following vaccination is also unclear.

Incidence

The number of new cases of a disease in a population during a particular time period. Calculating incidence rates can indicate how quickly an infectious disease is occurring in a population.

Incubation period

The time between being infected and showing symptoms. For COVID-19 this is about 5 days on average.

Index case

The patient in an outbreak of a disease who is first identified by health authorities.

LAMP test or RT-LAMP test (Reverse Transcription Loop-mediated isothermal AMPlification)

A scientific technique to detect and increase the amount of viral genetic material. Equipment using LAMP technology can be sited near to the person being tested and can give results in minutes instead of having to send samples for laboratory processing.

Lateral flow test

A type of molecular test to detect an active infection. The tests contain antibodies that bind to proteins (antigens) on the surface of the virus if it is present in a sample. A positive result is seen as a dark band or a fluorescent glow on the test kit, usually within minutes.

Mass spectrometry

A laboratory technique to identify specific molecules (such as viral proteins) in samples.

Mass testing

Using tests in a large sample of asymptomatic people to detect those who are currently infected.

Molecular test

A test that detects viral genetic material through PCR or newer laboratory techniques.

Morbidity

A term used to describe illness, injury or disability. Comorbidity or multimorbidity are sometimes used and refer to when someone has more than one condition at the same time.

Mortality

A term that means death. Mortality rates are an expression of the number of deaths for a given cause divided by the whole population.

Non-pharmaceutical interventions (NPIs)

Non-drug measures to limit the transmission of an infectious disease. These can be measures at the individual level such as physical distancing, the use of face masks and coverings, and improved hygiene measures. They can also be measures to constrain activities, such as the closures of various premises including sporting venues, pubs or shops.

PCR (Polymerase Chain Reaction) test

A specialised laboratory method used to increase the amount of DNA or RNA in a sample so there is enough to test it. PCR tests are used to detect RNA in samples from people to see if the samples contain SARS-CoV-2 virus.

Point-of-care test

A diagnostic test performed at or near to the person by a trained operator (like a urine dipstick to check for urinary tract infections).

Pooled testing

An approach to testing samples from a group of people using one test.

Prevalence

A measurement that expresses the proportion of people who have a disease at or during a given time period. Prevalence rates for disease are calculated by dividing the number of cases by the total number of people in the sample. They can be expressed as percentages or as cases per 100,000 people. It is often used alongside incidence, but they mean different things. While incidence counts only new cases in a given time period, prevalence counts both existing and new cases.

Primary case

The person who brings an infectious disease into a group of people, such as a country, city or workplace.

R (Reproduction Number)

A measure of how a disease spreads. The R number is the average number of people that one infected person will pass the virus onto. If R is more than 1 then an infection will spread in a population. Without any measures, the R for SARS-CoV-2 is 3.

Rapid test

While this refers to tests that can give a result in minutes rather than hours, the test may still require specialised equipment and/or trained operators.

Saliva test

A test that uses a saliva sample.

Self-sampling

Describes when a person takes their own sample that is then sent elsewhere for processing and interpretation of results.

Sensitivity

How well a test reports a positive result for people who have COVID-19.

Serial interval

The time between symptoms occurring in one person to symptoms appearing in the person they infect.

Specificity

How well a test reports a negative result for people who do not have COVID-19.

Swab test and self-swabbing

Transmission

Process by which a pathogen, like a virus, spreads from one infected person to another.

Terms used in research about COVID-19

Clinical trials

Phase 1

A small group of healthy people (<100) is given the vaccine to make sure there are no safety concerns, to see how well it stimulates an immune response and to work out an effective dose.

Phase 2

The vaccine is tested in a larger group (several hundred people) to see whether the vaccine works consistently, to assess the immune response and to look for side effects.

Phase 3

The vaccine is studied on a much larger scale (several thousand people) under natural disease conditions. This produces enough data to identify rare side effects and to evaluate how well the vaccine works in the real world; does it generate enough immunity to prevent and reduce di

Phase 4

After licensing, research continues to monitor any adverse effects and to determine long-term effectiveness. This activity is called pharmacovigilance.

Effectiveness

When discussing a drug such as a treatment for COVID-19 or a COVID-19 vaccine, this refers to how well the drug achieves the intended effect when it is used in real world settings. For example, while a therapeutic may reduce 90% of the disease (see efficacy) in a research study involving healthy young people under strict research conditions, this may not be achieved when it is used in a wider population of people with different characteristics, such as older people or those with underlying health conditions.

Efficacy

The extent to which a drug works as intended when it is tested in ideal circumstances such as in controlled research study. For example, a COVID-19 vaccine may have 90% efficacy at preventing the disease. This means that cases of the disease were reduced by 90% in vaccinated vs. non-vaccinated people in the study.

Human challenge study

Study where a pathogen is carefully given in controlled settings to healthy volunteers, who are therefore ‘challenged’ by it. These studies aim to better understand the infection process and find how to prevent and treat it.

Placebo

A substance or treatment that should have no clinical effect that is given to control groups so that the effects of an intervention can be distinguished from improvements that occur just from the placebo effect.

Randomised control trial

An experiment where participants are randomly placed into a control group or an intervention group. Cluster randomised controlled trials involve random assignment to the control or intervention at a group level (such as assigning whole schools, hospitals or local councils). They are considered a particularly robust study type as the randomisation reduces the likelihood of bias from extraneous variables. As experiments, they can demonstrate causation.

Terms used in drug development and COVID-19 treatments

Adverse event

This term is used to describe a range of reactions to drugs, including vaccines. They are sometimes called adverse drug reactions. Different drugs can produce varied effects. Side effects are those which can be linked to the vaccine. People can have reactions either as a direct result of the drug itself or because the individual has an underlying medical condition. Sometimes people may experience something when they take a drug, but which is completely unrelated. Extensive monitoring of drug safety can determine which reactions are linked to a drug from those that are not. Side effects from vaccines vary from predictable mild reactions such as a short-lived fever to more serious and rare outcomes such as allergic reaction.

Antibody therapy

Therapies based on antibodies against SARS-CoV-2 that can be used to treat COVID-19 patients.

Antivirals

Drugs used to prevent or treat viral infections. Some antivirals work by stopping the virus from entering cells while others inhibit stages of the viral life cycle, such as stopping the virus from replicating. Several antiviral drugs to treat COVID-19 are being evaluated but none has shown any significant clinical benefits so far in trials.

Convalescent plasma

A treatment that uses antibodies against SARS-CoV-2 taken from patients who have recovered from COVID-19. The theory is that the donated antibodies in the plasma can neutralise the virus while the patient’s own immune system mounts a response to the infection.

Dexamethasone

A steroid drug used to treat a range of inflammatory and allergic disorders. In hospitalised COVID-19 patients, it reduces deaths of ventilated patients by 35% and reduces deaths of patients requiring oxygen by 20%.

Good Manufacturing Practice (GMP)

This is the minimum standard that drug manufacturers must meet in the production process. This is to ensure that drugs are of consistent high quality across batches and that they meet the requirements specified by regulators in a drug’s marketing authorisation.

Licence to market a medicine

Also known as a marketing authorisation. Manufacturers must follow special procedures in order to sell a drug, such as a vaccine, in the UK and the EU. This is complex, with different processes depending on the medicine.

Monoclonal antibodies

Biological therapies synthesised in a laboratory. They mimic natural antibodies by recognising a specific target protein on a cell’s surfaces and then flagging these cells for killing, or by binding directly to the virus and stopping the virus from attaching to a human cell. Antibodies can be designed by using genetic sequences of interest from the virus. The main target of SARS-CoV-2 monoclonal antibodies is the spike protein on the surface of the virus, to block viral entry into cells.

Pharmacovigilance

Detecting, collecting and monitoring data about adverse events that may be linked to a medicine (such as a new drug or vaccine) so that appropriate action can be taken.

Proning

Positioning hospitalised COVID-19 patients on their stomachs. Research suggests that this benefits them because it improves oxygenation in the body.

Remdesivir

An experimental anti-viral drug. Research to date shows that it can reduce the time to recover for some patients.

Terms used to discuss the immune response to COVID-19, immunisations and vaccines

Active immune response

Immune response developed naturally by the body following the first encounter with a new pathogen. After a certain time, the body will start to produce antibodies able to specifically recognise the new pathogen.

Adenovirus-based vaccines

Vaccines where a harmless virus has been modified to contain the genetic information of a pathogen’s protein (antigen). Following vaccination, the body will produce this protein and develop an immune response against it. This strategy is used, for example, in the University of Oxford / AstraZeneca vaccine, which includes the genetic information of the SARS-CoV-2 spike protein.

Antibody

A ‘tag’ that binds specifically to part of a pathogen so that it can be recognised by the immune system. It is part of the ‘adaptive’ immune system and produced by B cells. Some antibodies are binding antibodies (they bind to the virus and activate parts of the immune system to enhance the body’s response) and some are neutralising antibodies (they are able to bind and stop the virus). There are different types of antibodies. Two important ones are:
IgM: the first antibodies produced by naïve B cells during the primary immune response. They are detected at similar levels during the secondary immune response. IgG: the major class of antibodies in the blood. They are produced during the primary immune response after IgM and their level increases substantially during the secondary response.

Attenuated vaccine

See live-attenuated vaccine.

B-cells

Type of white blood cell that produces antibodies. Naïve B cells are immature B cells not yet exposed to a pathogen. Once exposed, they can become memory B cells, able to secrete antibodies against that specific pathogen.

Booster dose

Extra dose of vaccine after the ‘prime dose’. It is used to boost the immune response against a pathogen.

Cold chain

Refers to the supply chain of some drugs and vaccines, which need to be in temperature-controlled environments, from production to delivery.

Cytokines

Chemicals signalling the presence of a pathogen in the body. They are part of the innate immune system and cause inflammation.

Disease modifying vaccine

Vaccines reducing the severity of diseases. In the case of COVID-19 for example, they can lead to fewer deaths following SARS-CoV-2 infection.

DNA-based vaccines

Vaccines where DNA instructions to build a pathogen’s protein are directly injected into the recipient. The US-based Inovio candidate or the Korean Genexine candidate use this strategy.

Herd immunity

When enough individuals in a population are immune to an infection so that those who are not immune are protected as well. It is also known as ‘population immunity’.

Immunisation

When individuals become protected from a disease, either following natural infection or vaccination.

Immune response

Response developed by the body when infected by a pathogen. Primary immune response is the first response triggered by exposure to a pathogen. Immature (naïve) B cells are stimulated by antigens, become activated, and start producing antibodies that stick to these antigens. There will be an initial surge of antibodies and then, with time, these antibody levels will decrease as the infection is cleared. Secondary immune response occurs during second and subsequent exposures to the same pathogen. Memory B cells are able to recognise the antigens that they have been previously exposed to and start producing antibodies in higher quantities than during the primary response.

Immunity

Ability to defend the body from a pathogen’s infection. Innate immunity consists of a series of non-specific mechanisms that prevent pathogens from invading the body. It includes physical barriers, such as the skin, and the cell linings of internal body parts, such as airways and lungs. The innate immune system also consists of several types of specialised cells and signalling chemicals. Acquired immunity describes how the body builds immunological memory – so that if the person is exposed to the same infection again the body’s response is enhanced. It is also known as ‘adaptive’ immunity. This is the basis for immunisation with vaccines. Key features of this adaptive response are that it is specific for the structures on a specific pathogen and that immune memory facilitates an improved response on subsequent encounters. It involves antibodies, B cells and T cells. This type of immunity can be strong or weak, short- or long-lived, and this is a complex result of several factors. It can take up to 3 weeks to develop this type of immunity.

Inactivated vaccine

Vaccines where a pathogen has been killed and therefore cannot multiply in the human body. The Valneva vaccine candidate uses this strategy. Live-attenuated vaccines use a weakened version of the pathogen that causes the disease. When injected, they resemble the natural infection and for this reason are able to trigger a strong immune response. mRNA vaccines containing mRNA, produce a pathogen’s antigen, that can be directly produced by the human body. This strategy is used in the Pfizer/BioNTech vaccine, which uses mRNA instructions to produce the SARS-CoV-2 spike protein.

Naturally acquired immunity

Immunity that is acquired when a person becomes infected by a pathogen and develops an immune response against it (see Active immune response and immune response).

Neutralising antibodies

Antibodies able to bind and stop the virus.

Prime dose

First dose of the vaccine, to trigger the initial immune response.

Passive immunity

When a person (who is not able to produce antibodies against a pathogen) receives them externally and become protected from the pathogen. This can be ‘maternal’, when antibodies are passed from the mother to the child (for example in breast milk) or ‘artificial’, when antibodies are administered via an injection (such as in the case of antibody therapy). It is not a long-lasting immunity.

Protein-based vaccines

Contain a protein found on the surface of a pathogen that is used to trigger the immune response. This strategy is used by the GSK / Sanofi Pasteur candidate.

Self-amplifying RNA

RNA able to create several copies of themselves before being read to make proteins. The Imperial College vaccine candidate uses this technology.

Sterilising vaccine

Vaccine able to stop the pathogen from replicating in the body, so that the infected person cannot transmit it to others.

Vaccination

Protecting individuals from a disease by treating them with a vaccine.

Vaccine

The most effective public health intervention to protect people against infectious diseases. Vaccines train the immune system to recognise a pathogen and to defend the body from it at the next encounter.

Vaccine candidate

New vaccine under development.

Vaccine coverage

Percentage of the population who has received a vaccine.

Vaccine take up

Accepting a vaccine when it is offered by public health authorities.

International organisations involved in public health and medicines regulation

CDC

Centers for Disease Control and Prevention. The US’s federal health protection agency.

EMA

European Medicines Agency. A European agency that facilitates development and access to medicines, and evaluates new medicines so that they can be approved for use in people.

FDA

Food and Drug Administration. A US agency that regulates the safety, effectiveness and quality of medicines. It has a wider role in public health such as food safety and regulating tobacco products.

WHO

World Health Organization. A UN agency focused on directing and coordinating international health.

UK organisations involved in public health, medicines regulation, decision-making and scientific advice in response to COVID-19

CSA

Chief Scientific Adviser. Most senior government adviser providing government departments with scientific advice. Most government departments have one. There are also CSAs for each of the devolved administration. The list is available here.

CMO

Chief Medical Officer. A qualified medical practitioner who is the most senior government adviser on health matters.

CHM

Commission on Human Medicines. An advisory non-departmental public body that advises ministers on the safety, efficacy and quality of medicinal products.

DHSC

Department for Health and Social Care. A ministerial government department with overall responsibility for health and care services. It sets strategy, funds and oversees the health and care system in England, with equivalent counterparts in the devolved nations.

GCSA

Government Chief Scientific Adviser. Chief Scientific Adviser providing scientific advice to the Prime Minister and members of Cabinet and coordinating the Chief Scientific Adviser network.

JCB

Joint Biosecurity Centre. Established in May 2020. It provides evidence-based analysis to inform local and national decision-making in response to COVID-19 outbreaks. It will become part of the NIHP once this is set up.

JCVI

Joint Committee on Vaccination and Immunisation. A scientific advisory committee that advises the UK health departments on immunisation.

MHRA

Medicines and Healthcare products Regulatory Agency. An executive agency of the Department of Health and Social Care. It regulates medicines, medical devices and blood components used in transfusions in the UK. It decides whether to approve new medicines such as vaccines.

NERVTAG

New and Emerging Respiratory Virus Threats Advisory Group. A scientific committee that advises the Government on the threat posed by new and emerging respiratory viruses. Advice from NERVTAG has been used by SAGE.

NICE

National Institute for Health and Care Excellence. An arm’s length body accountable to the Department of Health and Social Care but is independent of government. Its role is to improve patient outcomes by producing national guidance and advice, and quality standards that set out what high quality and cost-effective care should look like.

NIHP

National Institute for Health Protection. A new organisation responsible for public health protection. It will replace Public Health England and bring in other functions including the Joint Biosecurity Centre and NHS Test and Trace. It is expected to be operational in Spring 2021.

PHE

Public Health England. An executive agency of the Department of Health and Social Care, it is responsible for all aspects of public health from reducing health inequalities to responding to public health emergencies.

SAGE

Scientific Advisory Group for Emergencies. Provides scientific and technical advice to the UK Government during emergencies.

SPI-B

Independent Scientific Pandemic Influenza Group on Behaviours. A scientific committee that provides advice about behavioural science. In the context of COVID-19 the committee has provide advice about how people can be helped to adhere to interventions that have been recommended. It provides reports to SAGE.

SPI-M

Scientific Pandemic Influenza Group on Modelling. A scientific committee that provides advice on scientific matters relating to the UK’s response to infectious disease. Its advice is based on expertise on epidemiology and modelling. It reports to SAGE.

en_USEnglish
Share This